Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell ...

“Type II mAbs had been described as not crosslinking CD20 and using other killing mechanisms [than complement activation],” said Sauer. “It was a really big surprise to us that all the antibodies ...

Antibodies and related products are the fastest ... and associated with enhanced or silenced effector functions (ADCC or complement-dependent cytotoxicity) are being investigated in clinical ...

antibody-dependent cell-mediated cytotoxicity, and complement-dependent cytotoxicity, we expect ISB 1442 to overcome mechanisms of resistance to currently approved therapies”. The flexibility of ...